Dr Lynn Quek is a MRC Clinician Scientist and Consultant Haematologist specialising in caring for patients with Myelodysplasia (MDS) and Acute Myeloid Leukemia (AML). This is an area of unmet clinical need, particularly in patients who are unable to have toxic intensive treatment regimens.

The Myeloid Leukaemia Genomics and Biology group studies how clonal haematopoietic cell populations cause disease in blood and beyond. The group has a specific interest in evolution of disease across the spectrum of myeloid clonal disorders, from clonal haematopoiesis to MDS and AML. We are studying the biology of leukaemia stem cells and in epigenetic determinants of cell fate in MDS and AML. The group works to integrate multiple genomic and functional approaches, including single cell techniques to elucidate clonal structures, epigenetic and transcriptional heterogeneity. We currently have active research projects on clonal haematopoiesis, and on epigenetic mechanisms of differentiation arrest in MDS and AML. Our mission is to translate science into the best possible clinical care for patients.